Description
OVERVIEWProduct overview
ACE-031 is a soluble decoy receptor built from the extracellular domain of activin receptor type IIB fused to an Fc region.
It is studied as a ligand trap for myostatin and related TGF-beta family members.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
SUPPLY IN IRELANDACE-031 Ireland — supplied to research laboratories
Research groups across Ireland buy ACE-031 from Kensington Laboratories as a lyophilised ACE-031 peptide, released only against a batch-matched certificate of analysis. Every vial of high purity ACE-031 is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering ACE-031 in Ireland receive material with documented purity and identity.
Laboratory ACE-031 is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning ACE031 research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for ACE-031 peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
ACE-031 is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 1 mg per vial
- Peptide class: Soluble activin receptor type IIB fusion protein
- Also known as: ActRIIB-Fc fusion protein
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
ACE-031 is a soluble decoy receptor built from the extracellular domain of activin receptor type IIB fused to an Fc region.
It is studied as a ligand trap for myostatin and related TGF-beta family members.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Ligand trapping of myostatin and activin
- Muscle mass endpoints in rodent models
- Receptor binding selectivity
- Comparative work with anti-myostatin antibodies
Scientific context and proposed mechanisms
By binding circulating myostatin and activins before they reach cell-surface receptors, the fusion protein is described as reducing SMAD2/3 signalling.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-ACE031-2407A
- Testing laboratory
- Janoshik Analytical, s.r.o.
- Date tested
- 2 July 2026
- Reported purity
- 99.44%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
The independent result for this batch is summarised above. Contact the laboratory team if you need the full report for this batch.
